Tuesday 2 August 2022

Lupine Publishers| Comparative Stratification of Cardiovascular Risk through Framingham and Globo Risk in Patients with Psoriasis of IAHULA November 2017-May 2018.

 Lupine Publishers| Journal of Cardiology Research & Reports


Objectives: To know the frequency of Metabolic Syndrome in patients with Psoriasis who come to the consultation of the Dermatology Service of the Autonomous University Hospital of the Andes November 2017 to May 2018.

Materials and Methods: Observational analytical descriptive study. Patients with Psoriasis diagnoses who attended the dermatology office were selected, PASI, ATP-III, Framingham and GLOBORISK were applied.

Results: 55 patients, 55% men and 45% women, there was statistical correlation between older age groups and PASI index (p=0.023). The main modifiable cardiovascular risk factors were smoking, sedentary lifestyle and obesity, statistical correlation was found for sedentary lifestyle (p=0.047). The main non-modifiable cardiovascular risk factors were Hypertension and Diabetes showing both statistical significance (p=0.004), (p=0.0001). The ATP-III criteria showed statistical significance for Hypertension, glycemia, total cholesterol and low HDL (p=0.003, p=0.008, p=0.027, p=0.017). The frequency of metabolic syndrome represented 47.27% of the sample. The most affected gender was male (61.54%). Statistical correlation was found in the older age groups for the presence of Metabolic Syndrome (p=0.0001). The group with the highest frequency of metabolic syndrome was the one with 6 to 10 years of the disease (p=0.001). When applying the Framingham and GLOBORISK scores, there were higher scores in the patients as PASI was increased.

Conclusion: There is a higher frequency of Metabolic Syndrome in patients with Psoriasis, so it is recommended to establish measures aimed at reducing the burden of cardiovascular disease in these patients.

Keywords: Psoriasis; Metabolic Syndrome; Risk; Severity Index of the Disease


Psoriasis has evolved conceptually over time, from being considered a skin disease in its first descriptions, currently we can define it as a chronic and inflammatory skin disease, without a defined, genetically determined, pathophysiologically autoimmune etiology, of intermittent evolution, at risk of skin, systemic and psychological comorbidities, which impact on quality of life [1]. The most characteristic feature of psoriasis is the hyperproliferation and altered differentiation of keratinocytes, in addition to immune, biochemical, and vascular abnormalities influenced by multiple environmental factors that can trigger or exacerbate its evolution, affecting between 2 and 3% of the population. World [2]. Psoriasis is estimated to affect approximately more than 125 million people worldwide, with a global prevalence of 2-3%. Being greater in those of Caucasian origin, it is variable in other races and exceptional among the indigenous people of the American continent and Australia. The white race has a prevalence of 0.1% and the incidence in the black race is low. In Germany there is a prevalence of the disease of 1.7%, in Sweden of 2.3%, the United States 2.1%, India 0.7%, Japan 0.5%. In Latin American countries it is working on it. Studies suggest that the prevalence in South America is 1% [3].

According to the global report of psoriasis published by the WHO in 2016, people with psoriasis are at high risk of suffering from various comorbid conditions, such as cardiovascular disease, diabetes, obesity, Crohn’s disease, myocardial infarction, ulcerative colitis, metabolic syndrome, strokes or liver disease. Patients with moderate/severe psoriasis, especially in the 4th decade of life, have an increased risk of having a heart attack and survival decreases 3 years for men and 4 years for women because of cardiovascular events [4]. Epidemiological studies have aroused great interest in the association of psoriasis with different cardiovascular, metabolic and immune comorbidities with which it shares inflammatory pathways or a common background [5], however, its association with metabolic syndrome has been increasingly recognized [6]. Metabolic Syndrome (MS) is a set of cardiometabolic risk factors that confer a higher risk of developing cardiovascular disease than that attributed to each component in isolation. It affects approximately 15 to 25% of the general population, its prevalence is increasing both in developed countries (United States and European countries) and in developing countries, accompanying the increase in obesity globally [7,8]. Metabolic Syndrome confers a significant burden of disease, for example, some studies show that MS confers twice the risk of coronary artery disease, [9] as well as increases the risk of cerebrovascular disease, fatty liver and certain types of malignancies such as lymphomas and squamous cell carcinomas [10].

Current recommendations suggest that patients with psoriasis should be evaluated to rule out the presence of MS, and if it is present, they should receive intensive treatment, with interventions in their lifestyle, weight loss, control of blood pressure, diabetes, and hypercholesterolemia [11]. There are multiple criteria used to define metabolic syndrome at an international Mildl, those proposed by the International Diabetes Foundation (IDF), those of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and others such as those of the Organization World Health Organization (WHO) and the American Association of Clinical Endocrinologists (AACE) that have in common grouping a series of abnormalities in the same individual [12-14].

It should be noted that most of the research papers use the ATP III criteria to compare results due to their practical utility; associating simplicity to carry out laboratory tests; and it also requires complying with three of the five parameters. There is evidence that this association (SM/PSORIASIS) is due to increased T cell immune activity, and increased production of tumor necrosis factor alpha. These classify psoriasis as the prototype of an inflammatory disease characterized by TH1 and TH17 activation, whose cytokines such as IL1, IL6, and tumor necrosis factor alpha are elevated in blood and skin mediators that could have an effect on adipogenesis, lipid metabolism, and insulin signaling. Hence, the entire inflammatory process in psoriasis has a great impact on obesity, diabetes, thrombosis, and arteriosclerosis, which, in turn, can influence the pathogenesis of psoriasis by promoting the proinflammatory state and increasing the propensity to develop the syndrome. Metabolic [15-17].

Given that Psoriasis is one of the main reasons for consultation in the dermatological area, and having no current data on the incidence of MS in Venezuela, it is necessary to establish the prevalence of MS in patients with Psoriasis and subsequently establish if there is a correlation between both pathologies. It is important to highlight that in the autonomous institute university hospital of the Andes edo. Merida Venezuela no research work has been carried out that has determined the cardiovascular risk profile or the frequency of metabolic syndrome in patients with Psoriasis who come to the Dermatology service consultation of said institution, therefore an observational study of cross section in the period established from November 2017 to May 2018. It will be of great contribution and serve as health information, in addition to contributing to the prevention of said pathology and thus reducing morbidity and mortality. The motivation to carry out this study arises; and in turn, to instill future generations to continue the present investigation.



Stratification of cardiovascular risk using the Framingham and Globorisk scores in patients with Psoriasis who come to the Dermatology service consultation of the Autonomous Institute University Hospital of the Andes during the period from November 2017 to May 2018.


a. Know the demographic characteristics of the study population.
b. Describe the degree of severity of psoriasis lesions, according to the area index and severity of psoriasis (PASI).
c. Identify the Cardiovascular Risk factors in Psoriasis patients who come to the Dermatology service consultation at the Autonomous Institute Hospital Universitario de los Andes.
d. Identify the presence of the components of the metabolic syndrome, according to the ATP III criteria.
e. Establish statistical correlation between time of evolution of psoriasis, PASI index and SM.
f. Estimate cardiovascular risk according to the Framingham and GLOBORISK scales.
g. Establish correlation between cardiovascular risk/ psoriasis and metabolic syndrome/psoriasis.

Study design

Descriptive analytical observational study.

Population and sample

All patients who attended during the period from November 1, 2017 to May 31, 2018, with diagnoses of Psoriasis of both genders who attended the dermatology consultation of the Autonomous Institute Hospital Universitario de los Andes, and who met the inclusion criteria.

The inclusion criteria were as follows

a. Patients of both genders over 18 years of age.
b. Patients with a diagnosis of Psoriasis.
c. Informed consent signature.

Exclusion criteria

a. Immunological diseases, others.
b. Mixed connective tissue disease
c. Stage IV-V Chronic Kidney Disease
d. Neoplasm diagnosed.
e. Infectious processes in any form of presentation.

Data processing and analysis

Quantitative data were presented with measures of central tendency and dispersion (mean and standard deviation); the qualitative data were presented with absolute and relative frequencies (in percentages). The statistical association of qualitative data (bivariate analysis) was evaluated using the chisquare test, the statistical differences of quantitative data were evaluated using the Student’s t-test or ANOVA. The agreement between the Globo Risk and Framingham scales was evaluated through a Bland-Altman graph. Statistical significance was considered for values of p<0.05. Statistical analyzes and graphs were performed using SPSS version 21 (IBM Corporation, New York, US), Excel 2010 (Microsoft Corporation, Redmond, US) and GraphPad Prism version 5 (GraphPad Software Inc, La Jolla, USA).

Ethical component

The ethical components of this research work will be carried out based on the international ethical standards set forth in the Declaration of Helsinki [18] and that contemplated in the Code of Medical Deontology of the Venezuelan Medical Federation of March 20, 1985, in its Title V, Chapter 4, referring to research in human beings. It was requested to fill out the informed consent to the patients or their legal representatives when they are disabled, explaining in detail the purpose of the study; Likewise, the risk of complications that could arise with the taking of the sample, the confidentiality of the data obtained, the academic purposes and the non-intervention of the investigator in the treatment, as well as in the clinical evolution of the patient, will be explained. The economic resources for the realization of this study will be provided mostly by the author. This study has the support of the Autonomous Institute of the University Hospital of the Andes (IAHULA), the Multidisciplinary Laboratory of Clinical-Epidemiological Research (Lab-MICE) of IAHULA, the Department of Internal Medicine, the Dermatology department of IAHULA.


Table 1 showed that the study sample was made up of 55 patients who attended the IAHULA Dermatology clinic, distributed by gender as follows; female gender n=25 with a respective percentage of (45.5%) and the highest proportion male gender n=30 (54.5%). The patients were stratified according to the PASI classification in 4 categories; inactive or asymptomatic forms, Mild, Moderate, and finally the severe and very severe forms in the last group as a last category to simplify their subsequent analysis. It was evidenced that the Moderate form of the disease according to the PASI index was the one with the highest frequency n=22, with a gender distribution of 10 (45.5%) for the female and 12 (55.5) for the gender. male. Regarding age groups, they were divided into 4 categories: those under 30 years, between 31 to 50 years, 51 to 60 years, and those over 60 years, respectively. The highest proportion of patients corresponded to the group over 60 years old (16), secondly those between 31 and 50 years old (14), thirdly between 51 and 60 years old (13) and lastly those under 30 years old (12) this correlation between the age of the patients and the PASI index being statistically significant.

Read More About Lupine Publishers Journal of Cardiology Research & Reports Please Click on Below Link: https://lupine-publishers-cardiovascular.blogspot.com/

No comments:

Post a Comment

Note: only a member of this blog may post a comment.